EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Motifs in Vascular Morphogenesis: Vascular Endothelial Growth Factor A (VEGFA) as the Leading Promoter of Angiogenesis

Claudiu N Lungu iD, Mihaela C Mehedinti

International Journal of Molecular Sciences · 29.07.2023 · 24 (15) · 12169

DOI: 10.3390/ijms241512169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.07.2023. Verfasst von Claudiu N Lungu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departament of Functional and Morphological Science, Faculty of Medicine and Pharamacy, Dunarea de Jos University, 800010 Galati, Romania. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Peripheral Arterial Disease. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tissular hypoxia stimulates vascular morphogenesis. Vascular morphogenesis shapes the cell and, consecutively, tissue growth. The development of new blood vessels is intermediated substantially through the tyrosine kinase pathway. There are several types of receptors inferred to be located in the blood vessel structures. Vascular endothelial growth factor A (VEGF-A) is the leading protagonist of angiogenesis. VEGF-A’s interactions with its receptors VEGFR1, VEGFR2, and VEGFR3, together with disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1), connective tissue growth factor (CTGF), and neuropilin-1 (NRP1), independently, are studied computationally. Peripheral artery disease (PAD), which results in tissue ischemia, is more prevalent in the senior population. Presently, medical curatives used to treat cases of PAD—antiplatelet and antithrombotic agents, statins, antihypertensive remedies with ACE (angiotensin-converting enzyme) impediments, angiotensin receptor blockers (ARB) or β- blockers, blood glucose control, and smoking cessation—are not effective. These curatives were largely established from the treatment of complaint cases of coronary disease. However, these medical curatives do not ameliorate lower limb perfusion in cases of PAD. Likewise, surgical or endovascular procedures may be ineffective in relieving symptoms. Eventually, after successful large vessel revascularization, the residual microvascular circulation may well limit the effectiveness of curatives in cases of PAD. It would thus feel rational to attempt to ameliorate perfusion in PAD by enhancing vascular rejuvenescence and function. Likewise, stimulating specific angiogenesis in these cases (PAD) can ameliorate the patient’s symptomatology. Also, the quality of life of PAD patients can be improved by developing new vasodilative and angiogenetic molecules that stimulate the tyrosine kinase pathway. In this respect, the VEGFA angiogenetic pathway was explored computationally. Docking methodologies, molecular dynamics, and computational molecular design methodologies were used. VEGFA’s interaction with its target was primarily studied. Common motifs in the vascular morphogenesis pathway are suggested using conformational energy and Riemann spaces. The results show that interaction with VEGFR2 and ADAMTS1 is pivotal in the angiogenetic process. Also, the informational content of two VEGFA complexes, VEGFR2 and ADAMTS1, is crucial in the angiogenesis process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor APeripheral Arterial DiseaseHumansAngiotensin Receptor AntagonistsQuality of LifeAngiotensin-Converting Enzyme InhibitorsVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Morphogenesis

Stichwörter der Autor:innen

VEGF-AVEGFRangiogenesisconformational analysismolecular descriptorsprotein dockingvascular morphogenesis

Substanzen

Vascular Endothelial Growth Factor AAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2VEGFA protein, human

Autor:innen und Institutionen

  • Departament of Functional and Morphological Science, Faculty of Medicine and Pharamacy, Dunarea de Jos University, 800010 Galati, Romania.

ORCID-Profile: Claudiu N Lungu

Zitieren

APA

Lungu, C. N., & Mehedinti, M. C. (2023). Molecular Motifs in Vascular Morphogenesis: Vascular Endothelial Growth Factor A (VEGFA) as the Leading Promoter of Angiogenesis. International Journal of Molecular Sciences, 24(15), 12169. https://doi.org/10.3390/ijms241512169

Vancouver

Lungu CN, Mehedinti MC. Molecular Motifs in Vascular Morphogenesis: Vascular Endothelial Growth Factor A (VEGFA) as the Leading Promoter of Angiogenesis. International Journal of Molecular Sciences. 2023;24(15):12169. doi:10.3390/ijms241512169

BibTeX
@article{Lungu2023,
  author = {Lungu, Claudiu N and Mehedinti, Mihaela C},
  title = {Molecular Motifs in Vascular Morphogenesis: Vascular Endothelial Growth Factor A (VEGFA) as the Leading Promoter of Angiogenesis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {15},
  pages = {12169},
  doi = {10.3390/ijms241512169}
}
Kostenlos starten →